AC
RNAC icon

Armistice Capital’s Cartesian Therapeutics RNAC Stock Holding History

Armistice Capital’s Portfolio RNAC Stock Details RNAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-98,565
Closed -$1.59M – 293
2024
Q3 		$1.59M Buy
+98,565
New +$1.54M 0.03% 161
2021
Q1 		– Sell
-54,533
Closed -$4.96M – 127
2020
Q4 		$4.96M Buy
+54,533
New +$4.73M 0.17% 83

Other funds holding RNAC

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Armistice Capital's RNAC Position: Q4 2024 in Review

Armistice Capital sold out of Cartesian Therapeutics (RNAC) in Q4 2024, closing a stake of 98,565 shares — an estimated $1.59M sold.

Armistice Capital first reported a position in RNAC in Q4 2020 and held it in 2 quarters. The position peaked at $4.96M in Q4 2020. 68 funds tracked by Wall St. Rank hold RNAC as of Q4 2024.

  • Armistice Capital reported no remaining Cartesian Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Armistice Capital sold 98,565 Cartesian Therapeutics shares in Q4 2024, an estimated $1.59M.
  • Armistice Capital first reported a position in Cartesian Therapeutics in Q4 2020 and held it in 2 quarters.
  • Armistice Capital's Cartesian Therapeutics position peaked at $4.96M in Q4 2020.
  • 68 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q4 2024.

Based on Armistice Capital's 13F filing for Q4 2024, filed 14 Feb 2025.